Consensus on the treatment of alopecia areata - Brazilian Society of Dermatology

• Autor(a) principal: Ramos, Paulo Muller [UNESP]
• Data de Publicação: 2020
• Outros Autores: Anzai, Alessandra, Duque-Estrada, Bruna, Melo, Daniel Fernandes, Sternberg, Flavia, Nogueira Santos, Leopoldo Duailibe, Alves, Lorena Dourado, Mulinari-Brenner, Fabiane
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1016/j.abd.2020.05.006; http://hdl.handle.net/11449/210008
• topic: Adrenal cortex hormones; Alopecia areata; Consensus; Methotrexate; Therapeutics

Background: Alopecia areata is a highly frequent disease with an impact on quality of life and several treatment options with little clinical confirmatory evidence. Objective: To disseminate the recommendations of Brazilian dermatologists with expertise in the treatment of alopecia areata. Methods: Eight specialists with expertise in alopecia areata from different university centers were appointed by the Brazilian Society of Dermatology to reach a consensus on its treatment. Based on the adapted DELPHI methodology, the relevant elements were considered; then, an analysis of recent literature was carried out and the consensus was written down. Consensus on the management of alopecia areata was defined with the approval of at least 70% of the panel. Results/Conclusions: Intralesional injectable corticotherapy was considered the first optionfor localized disease in adults. In extensive cases with signs of activity, systemic cortico-steroid therapy should be considered and can be used together with immunosuppressants (corticosteroid-sparing agents). The use of an immunosensitizer (diphencyprone) is an option for stable long-term cases. Evaluation of side effects is as important as the rate of hair regrowth. (C) 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana, S.L.U.